TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC
Clinical trial NCT04592029 · COMPLETED
Trial details
- NCT number
- NCT04592029
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-10-21
- Primary completion
- 2023-02-07
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.